Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 3/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.46 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.45 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.42 |
| ▸ | CALCR | P30988 | 6/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430993 | 0.94 | NAA50 (0.56) | NAA50APLNRNTSR1NMUR2NMUR1 | |
| SCHEMBL29800885 | 0.90 | NAA50 (0.47) | NAA50APLNRNTSR1NMUR2NMUR1 | |
| SCHEMBL30853585 | 0.89 | NAA50 (0.48) | NAA50APLNRNTSR1NMUR2NMUR1 | |
| SCHEMBL30608626 | 0.89 | NAA50 (0.53) | NAA50APLNRNTSR1NMUR2NMUR1 | |
| SCHEMBL29800494 | 0.87 | OPRM1 (0.44) | APLNRNMUR2NMUR1RAMP3CALCR | |
| SCHEMBL30608607 | 0.87 | NAA50 (0.53) | NAA50APLNRNTSR1NMUR2NMUR1 | |
| SCHEMBL31670630 | 0.87 | NAA50 (0.51) | NAA50APLNRNTSR1 | |
| SCHEMBL29569646 | 0.87 | NAA50 (0.52) | NAA50APLNRNMUR2NMUR1RAMP3 | |
| SCHEMBL31191354 | 0.86 | NAA50 (0.49) | NAA50APLNRNTSR1RAMP3CALCR | |
| SCHEMBL30563219 | 0.86 | NAA50 (0.44) | NAA50NTSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| EP-1409017-A4 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1409017-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | Drug Innovation & Design, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | DRUG INNOVATION & DESIGN, INCORPORATED | 2003-02-13 | — | — | US | disclosed |
| WO-2003000201-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN, INCORPORATED (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | EPHA2, EEA1, TPX2 | NAA50 3839/4885APLNR 166/4885NTSR1 1973/4885 |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | NAA50 3669/4885APLNR 158/4885NTSR1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.